TABLE 1.
Demographic, Cognitive, and Neuropathologic Features for the 4 Groups
| Subject | Age, year | Sex | MMSE | Path Dx | CERAD* | Braak† |
|---|---|---|---|---|---|---|
| Age-Matched C | ||||||
| 1 | 92 | M | 30 | C | 0 | II |
| 2 | 79 | M | 29 | C | 0 | 0 |
| 3 | 93 | F | 30 | C | 0 | II |
| 4 | 81 | M | 30 | C | 0 | II |
| 5 | 69 | M | 29 | C | 0 | II |
| 6 | 86 | M | 30 | C | 0 | II |
| 7 | 80 | M | 29 | C | 0 | II |
| 8 | 80 | M | 29 | C | 0 | 0 |
| 9 | 71 | F | 28 | C | 0 | II |
| 10 | 84 | M | 30 | C | 0 | II |
| 11 | 99 | M | 28 | C | 0 | IV |
| 12 | 86 | M | 28 | C | 0 | IV |
| 13 | 95 | M | 30 | C | 0 | III |
| 14 | 77 | M | 30 | C | 0 | II |
| 15 | 88 | M | 30 | C | 0 | II |
| Mean ± SE | 84.0 ± 2.2 | 29.2 ± 0.2 | ||||
| ASYMAD | ||||||
| 16 | 93 | M | 30 | poAD | B | 0 |
| 17 | 83 | M | 29 | poAD | B | II |
| 18 | 91 | M | 30 | poAD | B | III |
| 19 | 79 | M | 28 | poAD | B | II |
| 20 | 96 | M | 29 | poAD | B | IV |
| 21 | 93 | M | 30 | poAD | C | IV |
| 22 | 94 | M | 30 | poAD | B | III |
| 23 | 85 | F | 29 | poAD | B | III |
| 24 | 95 | F | 28 | poAD | B | IV |
| 25 | 75 | M | 30 | poAD | C | II |
| 26 | 92 | M | 30 | poAD | B | IV |
| 27 | 94 | M | 29 | poAD | B | IV |
| 28 | 71 | M | 30 | poAD | C | III |
| 29 | 75 | M | 29 | poAD | C | IV |
| 30 | 92 | F | 30 | poAD | B | IV |
| Mean ± SE | 87.2 ± 2.1 | 29.4 ± 0.1 | ||||
| MCI | ||||||
| 31 | 77 | M | 26 | prAD | B | 0 |
| 32 | 69 | M | 27 | prAD | A | II |
| 33 | 81 | M | 29 | prAD | B | IV |
| 34 | 89 | F | 23 | prAD | B | III |
| 35 | 96 | M | 28 | prAD | B | II |
| 36 | 89 | M | 26 | prAD | B | IV |
| 37 | 87 | M | 25 | prAD | B | IV |
| 38 | 90 | M | 29 | prAD | B | IV |
| 39 | 99 | M | 22 | prAD | B | IV |
| 40 | 89 | M | 27 | poAD | A | IV |
| 41 | 90 | M | 26 | prAD | B | II |
| 42 | 88 | F | 26 | poAD | A | III |
| 43 | 82 | M | 29 | prAD | B | IV |
| 44 | 78 | M | 27 | prAD | B | IV |
| 45 | 101 | F | 19 | poAD | B | IV |
| Mean ± SE | 87.0 ± 2.2 | 25.9 ± 0.7 | ||||
| AD | ||||||
| 46 | 89 | M | 17 | deAD | C | IV |
| 47 | 96 | M | 24 | deAD | C | VI |
| 48 | 97 | M | 26 | deAD | C | II |
| 49 | 98 | M | 23 | deAD | C | IV |
| 50 | 90 | F | 17 | deAD | B | IV |
| 51 | 85 | M | 17 | deAD | B | IV |
| 52 | 95 | F | 5 | deAD | B | IV |
| 53 | 88 | M | 24 | deAD | C | VI |
| 54 | 85 | M | 10 | deAD | B | III |
| 55 | 95 | M | 26 | deAD | B | IV |
| 56 | 82 | F | 22 | deAD | C | VI |
| 57 | 92 | M | 4 | deAD | C | VI |
| 58 | 94 | F | 9 | deAD | C | VI |
| 59 | 94 | F | 23 | deAD | C | VI |
| 60 | 101 | F | 10 | deAD | B | IV |
| Mean ± SE | 92.0 ± 1.3 | 17.1 ± 2.1 |
*
CERAD age-adjusted neuritic plaque score.
†
Braak scoring for neurofibrillary tangles.
AD, Alzheimer disease; ASYMAD, asymptomatic AD; C, control; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; dead, definite AD; F, female; M, male; MCI, mild cognitive impairment; MMSE, Mini Mental State Examination; Path Dx: Pathologic diagnosis according to CERAD; poAD, possible AD; prAD, probable AD; SE, standard error.